New Way to Manage Polycythemia Vera

What if patients with polycythemia vera (PV) could need fewer phlebotomies—and gain more freedom? In this video, Dr. Robert A. Figlin speaks with Dr. Andrew Kuykendall about promising data from the VERIFY Phase 3 trial, presented at ASCO 2025. They explore rusfertide, a new treatment being studied as a complement to ruxolitinib in polycythemia vera, which may help maintain safe blood counts and reduce the need for frequent phlebotomy in polycythemia management. Delivered as a weekly injection, rusfertide could offer a simpler, more empowering future for patients. 📌 Discover how this therapy may reshape the landscape of new treatments for polycythemia vera. 🧬 Follow more from our ASCO 2025 conference coverage: ➡️ https://bit.ly/3RUSDKQ 🔔 Subscribe for the latest breakthroughs in MPN research and patient care. #RuxolitinibPolycythemiaVera #PolycythemiaVera #PhlebotomyInPolycythemia #NewTreatmentsForPolycythemiaVera #PatientPower